Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects
Version of Record online: 9 APR 2014
© 2014 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
The Journal of Clinical Pharmacology
Volume 54, Issue 9, pages 995–1005, September 2014
How to Cite
Green, J. A., Patel, A. K., Patel, B. R., Hussaini, A., Harrell, E. J., McDonald, M. J., Carter, N., Mohamed, K., Duparc, S. and Miller, A. K. (2014), Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects. Journal of Clinical Pharma, 54: 995–1005. doi: 10.1002/jcph.302
[The copyright line for this article was changed on 28 October 2014 after original online publication.]
Author contributions: JAG, AKP, EJH, AKM, NC, KM and SD developed the protocol. JAG, AH and AKP oversaw the clinical study. AH and MJMcD were involved in data acquisition. AKM and BRP conducted the pharmacokinetic analysis and the pharmacokinetic/pharmacodynamic modelling. NC, MJMcD and KM provided statistical input into data analysis. All authors contributed to this manuscript and approved the final version for submission.
- Issue online: 5 AUG 2014
- Version of Record online: 9 APR 2014
- Accepted manuscript online: 3 APR 2014 04:27AM EST
- Manuscript Accepted: 1 APR 2014
- Manuscript Received: 5 FEB 2014
- 7http://apps.who.int/medicinedocs/en/d/Jh2922e/ Accessed 2nd February, 2013.. WHO Model Prescribing Information: Drugs Used in Parasitic Diseases—Second Edition. World Health Organization. Available at:
- 27International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs. E14, Step 5. ICH Steering Committee. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf Accessed 24th February, 2013.